Karyopharm Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 36.01 million compared to USD 36.15 million a year ago. Net loss was USD 34.51 million compared to USD 36.32 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.45 a year ago.
For the nine months, revenue was USD 112.29 million compared to USD 123.49 million a year ago. Net loss was USD 101.26 million compared to USD 126.79 million a year ago. Basic loss per share from continuing operations was USD 0.89 compared to USD 1.6 a year ago.